Cabazitaxel
Back to searchMolecule Structure
Scientific Name
Cabazitaxel
Description of the Drug
Cabazitaxel is an antineoplastic agent used for the treatment of hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06772
http://www.drugbank.ca/drugs/DB06772
Brand Name(s)
Jevtana, Jevtana kit
Company Owner(s)
Accord Healthcare Inc, Breckenridge Pharmaceutical Inc, Sanofi Aventis Us Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Tubulin | PROTEIN COMPLEX GROUP | INHIBITOR | CHEMBL2095182 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL179674 | |
| PharmGKB | PA165958401 | |
| Human Metabolome Database | HMDB0015672 | |
| DrugBank | DB06772 | |
| PubChem: Thomson Pharma | 14816121 | 16397389 |
| PubChem | 9854073 | |
| Nikkaji | J2.871.889F | |
| EPA CompTox Dashboard | DTXSID40171389 | |
| DrugCentral | 4153 | |
| ChemicalBook | CB42517227 | |
| Guide to Pharmacology | 6798 | |
| rxnorm | JEVTANA | CABAZITAXEL |
| ChEBI | 63584 | |
| ZINC | ZINC000085536932 |
